This study aims to evaluate the efficacy and side effects of low dose cyclophosphamide chemotherapy plus meloxicam as an adjuvant treatment, compared with high dose doxorubicin or surgery alone in cats with mammary carcinoma. Medical records of 228 female cats treated for mammary carcinoma between 2008 and 2018, were reviewed in eight veterinary institutions. Only cats with complete tumour staging and radical mastectomy were included in the study. One hundred and thirty-seven cats were divided into three treatment groups: group 1 (n = 80) cats treated with surgery, group 2 (n = 34) cats that had surgery and adjuvant treatment with doxorubicin, and group 3 (n = 23) cats with surgery and adjuvant treatment with low dose metronomic cyclophosphamide and meloxicam. The study endpoints were disease free interval (DFI) and overall survival (OS). Toxicity was evaluated according to the VCOG-CTCAE criteria. The median DFI was 270, 226 and 372 days in groups 1, 2 and 3, respectively. The median OS was 338 (group 1), 421 (group 2) and 430 (group 3) days. The differences between groups were not significant (DFI P = .280 and OS P = .186). Toxicity was observed in 52.9% (n = 18) of cats in group 2 and 39.1% (n = 9) of cats in group 3, with mild to moderate intensity. Differences were not significant (P = .306). In conclusion, adjuvant chemotherapy treatment did not improve survival and the overall benefit remains unproven. Randomized prospective trials are necessary to clarify the effectiveness of adjuvant chemotherapy treatment for feline mammary carcinomas.

中文翻译：

---

辅助多柔比星 vs 节拍环磷酰胺和美洛昔康 vs 单独手术治疗猫患乳腺癌：137 例回顾性研究

本研究旨在评估低剂量环磷酰胺化疗联合美洛昔康作为辅助治疗的疗效和副作用，与高剂量阿霉素或单独手术治疗患乳腺癌的猫进行比较。在 8 个兽医机构审查了 2008 年至 2018 年间因乳腺癌治疗的 228 只母猫的医疗记录。该研究仅包括具有完整肿瘤分期和根治性乳房切除术的猫。137 只猫分为三个治疗组：第 1 组 (n = 80) 接受手术治疗的猫、第 2 组 (n = 34) 接受手术和阿霉素辅助治疗的猫和第 3 组 (n = 23 ) 用低剂量节拍环磷酰胺和美洛昔康进行手术和辅助治疗的猫。研究终点是无病间隔（DFI）和总生存期（OS）。根据 VCOG-CTCAE 标准评估毒性。第 1、2 和 3 组的中位 DFI 分别为 270、226 和 372 天。中位 OS 为 338（第 1 组）、421（第 2 组）和 430（第 3 组）天。组间差异不显着（DFIP  = .280 和 OS P  = .186）。在第 2 组 52.9% (n = 18) 的猫和第 3 组 39.1% (n = 9) 的猫中观察到毒性，强度为轻度至中度。差异不显着（P  = .306）。总之，辅助化疗治疗并没有提高生存率，总体益处仍未得到证实。有必要进行随机前瞻性试验来阐明辅助化疗治疗猫乳腺癌的有效性。